Last reviewed · How we verify
IN-C006 Peri inj.
IN-C006 Peri inj. is a drug that targets the PD-1/PD-L1 pathway.
IN-C006 Peri inj. is a drug that targets the PD-1/PD-L1 pathway. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | IN-C006 Peri inj. |
|---|---|
| Sponsor | HK inno.N Corporation |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the PD-1/PD-L1 interaction, IN-C006 Peri inj. aims to restore the body's immune response against cancer cells. This mechanism is thought to be effective in treating various types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IN-C006 Peri inj. CI brief — competitive landscape report
- IN-C006 Peri inj. updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI